LIM and SH3 Domain Protein 1 (LASP-1) Overexpression Was Associated with Aggressive Phenotype and Poor Prognosis in Clear Cell Renal Cell Cancer

Yang, Fan; Zhou, Xiaoting; Du, Shuangkuan; Zhao, Yongjun; Ren, Wei; Deng, Qian; Wang, Fuli; Yuan, Jianlin

doi:10.1371/journal.pone.0100557

Cited by 28 publications

(30 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A-498, the 786-0 cells exhibit higher expression of LIM and SH3 protein 1 (LASP-1), which correlated with aggressive phenotype and poor prognosis in RCC (20). Thus, the more aggressive cell line 786-0 was selected to investigate whether honokiol inhibits cell migration under the incubation time (3 h) and concentrations (0-40 µM) that do not affect viability of 786-0 cells.…”

Section: Honokiol Inhibits Migration Of 786-0 Cells Comparing Withmentioning

confidence: 99%

“…In this study, we first demonstrate that honokiol suppresses proliferation of human RCC A-498 and 786-0 cells without affecting cell viability. In addition, honokiol inhibits migration of highly metastatic RCC 786-0 (19,20) and stimulates RhoA activity. Furthermore, phosphorylated MLC and excessive formation of actin stress fibers were identified in 786-0 cells treated with honokiol.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Honokiol inhibits migration of renal cell carcinoma through activation of RhoA/ROCK/MLC signaling pathway

Cheng

Castillo

Welty

et al. 2016

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. Honokiol, a biologically active compound isolated from Magnolia bark, has been shown to possess promising anticancer effect through induction of apoptosis. However, there is a relative lack of information regarding its anti-metastatic activity. Renal cell carcinoma (RCC) is the most common malignancy of the adult kidney and is known for high risk of metastasis. Clinically, therapeutic methods for metastatic RCC cases are limited and efforts to exploit new treatments are still ongoing. The results of our current investigation first revealed that honokiol suppressed the proliferation of different human RCCs without affecting cell viability. In addition, honokiol inhibited migration of highly metastatic RCC 786-0 cells and stimulated the activity of small GTPase, RhoA. Furthermore, phosphorylated myosin light chain (MLC) and excessive formation of actin stress fibers were identified in 786-0 cells treated with honokiol. Interestingly, the pharmacological Rho-associated protein kinase (ROCK) inhibitor Y-27632 attenuated contraction of actin stress fibers induced by honokiol and abrogated honokiol-mediated inhibition of cell migration. Together these important findings suggest that honokiol suppresses the migration of highly metastatic RCC through activation of RhoA/ROCK/MLC signaling and warrants attention in the treatment of RCC metastasis as a novel therapeutic approach.

show abstract

Section: Honokiol Inhibits Migration Of 786-0 Cells Comparing Withmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Honokiol inhibits migration of renal cell carcinoma through activation of RhoA/ROCK/MLC signaling pathway

Cheng

Castillo

Welty

et al. 2016

International Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…LASP-1 is a speci c focal adhesion protein that has been demonstrated to play an important role in cancer development and progression [13,[29][30][31]. For instance, Frietsch et al analyzed the prognostic signi cance of LASP-1 in breast cancer patients and provided evidence that nuclear LASP-1-positivity may serve as a negative prognostic indicator for long-term survival of breast cancer patients [13].…”

Section: Discussionmentioning

confidence: 99%

“…Wang et al determined the expression of LASP-1 in primary HCC and the results showed that the high cytosolic LASP-1 expression was associated with poor overall survival in HCC patients [30]. Yang et al examined LASP-1 expression in ccRCC tissues and in two cell lines and the results indicated that LASP-1 might serve as a prognostic biomarker for ccRCC patients [31]. Based on the previous reports, we studied the clinical diagnostic value of LASP-1 in CCA.…”

Section: Discussionmentioning

confidence: 99%

LIM and SH3 Protein 1 Stands for a Bio-Marker for Cholangiocarcinoma Detection

Wang¹,

Li²,

Zheng³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: LIM and SH3 protein 1 (LASP-1) has been demonstrated to be overexpression in several types of cancers. The aim of this study was to verify the serum level of LASP-1 and investigate its diagnostic value in cholangiocarcinoma (CCA) patients.Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to detect the expression level of LASP-1 in CCA patients and healthy controls. The correlation of LASP-1 expression with clinicopathological characteristic of CCA patients was analyzed via Chi-square test. Receiver operating characteristic (ROC) curve was built to evaluate the diagnostic value of serum LASP-1 in CCA.Results: Serum levels of LASP-1 were upregulated in CCA compared with healthy controls (P<0.01). And the serum level and tissue level of LASP-1 mRNA exhibited significant correlation (R=0.454, P=0.000). Serum expression of LASP-1 was closely associated with lymph node metastasis (P=0.018) and TNM stage (P=0.021). ROC curve analysis revealed that serum LASP-1 was of great value in differentiating CCA patients from healthy individuals. The area under the ROC curve (AUC) value was 0.879 corresponding with a sensitivity of 81.9% and a specificity of 79.6%.Conclusions: Serum LASP-1 might be an useful diagnostic biomarker for CCA.

show abstract

“…invasion, and metastasis process. [8][9][10][11][12][13][14][15] However, unlike Lasp1, little is known about the function of Lasp2 in human cancers.…”

mentioning

confidence: 99%

Lasp2 enhances tumor invasion via facilitating phosphorylation of FAK and predicts poor overall survival of non‐small cell lung cancer patients

Zhang

Cai

Zhou

et al. 2017

Molecular Carcinogenesis

View full text Add to dashboard Cite

Lasp2, as well as Lasp1, is a member of the LIM-protein subfamily of the nebulin group characterized by the combined presence of LIM and SH3 domains. Lasp1 and Lasp2 are highly conserved in their LIM, nebulin-like, and SH3 domains but differ significantly at their linker regions. Lasp1 had been described as an oncogenic protein that was highly expressed in diverse cancer types and facilitated tumor proliferation, invasion, and metastasis process. However, unlike Lasp1, little is known about the functions of Lasp2. In the present study, using immunohistochemistry, we found that Lasp2 expression was significantly correlated with histological type (P = 0.012), advanced TNM stage (P = 0.024), positive regional lymph node metastasis (P = 0.035), and poor overall survival (P = 0.001). Would healing assay and transwell assay results indicated that Lasp2 promoted tumor migration and invasion in NSCLC cells. Furthermore, Lasp2 facilitated Snail expression and inhibited Zo-1. The levels of phosphorylated FAK (Tyr397 and Tyr925) were obviously increased after overexpressing Lasp2 and were downregulated by transfecting Lasp2-siRNA. FAK inhibitor counteracted upregulating Snail expression and downregulating of Zo-1 expression induced by Lasp2 overexpression. Taken together, Lasp2 may facilitate tumor migration and invasion of NSCLCs through FAK-Snail/Zo-1 signaling pathway. Lasp2 may be a potential prognostic predictor of NSCLC patients.

show abstract

LIM and SH3 Domain Protein 1 (LASP-1) Overexpression Was Associated with Aggressive Phenotype and Poor Prognosis in Clear Cell Renal Cell Cancer

Cited by 28 publications

References 22 publications

Honokiol inhibits migration of renal cell carcinoma through activation of RhoA/ROCK/MLC signaling pathway

Honokiol inhibits migration of renal cell carcinoma through activation of RhoA/ROCK/MLC signaling pathway

LIM and SH3 Protein 1 Stands for a Bio-Marker for Cholangiocarcinoma Detection

Lasp2 enhances tumor invasion via facilitating phosphorylation of FAK and predicts poor overall survival of non‐small cell lung cancer patients

Contact Info

Product

Resources

About